Probing (Orphan) Nuclear Receptors in Neurodegeneration
Neurodegenerative diseases such as Alzheimer’s, Parkinson’s or Multiple Sclerosis are severe health burdens and major global challenges for societies and healthcare systems. Therapeutic interventions in these diseases are not sati...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
MTD4ALS
Development of inovative multi target drugs for ALS
160K€
Cerrado
CTQ2015-68380-R
NUEVAS MOLECULAS MULTIDIANA Y TERANOSTICAS PARA EL DIAGNOSTI...
155K€
Cerrado
NeuroProtect
Novel Drug Therapy with Potential to Cure Neuro Degenerative...
71K€
Cerrado
PHOTOLEG
Development of Photochromic Ligands for Selectively Expresse...
162K€
Cerrado
Neurotoxic
An Ultra sensitive Assay to Measure Oligomer Induced Toxicit...
195K€
Cerrado
PID2021-127833OB-I00
NUEVAS ESTRATEGIAS TERAPEUTICAS PARA EL TRATAMIENTO DE TRAST...
109K€
Cerrado
Información proyecto NeuRoPROBE
Duración del proyecto: 60 meses
Fecha Inicio: 2022-04-26
Fecha Fin: 2027-04-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Neurodegenerative diseases such as Alzheimer’s, Parkinson’s or Multiple Sclerosis are severe health burdens and major global challenges for societies and healthcare systems. Therapeutic interventions in these diseases are not satisfying, since there is no treatment strategy that can halt or reverse disease progression. Several failed attempts at finding a cure for neurodegeneration have significantly reduced the interest for further research - yet, more than ever, new approaches are needed. Critically missing are pharmacologically validated targets for efficient neurodegenerative disease treatment and it is exactly here that NeuRoPROBE aims to close this gap. The orphan nuclear receptors (NR) tailless homologue (TLX) and nuclear receptor related-1 protein (Nurr1) have been identified in knockout studies as prime candidates. However, ligands for their pharmacological control as tools for therapeutic validation are lacking. NeuRoPROBE will enable pharmacological modulation of these transcription factors as a new and groundbreaking strategy to counteract neurodegeneration.
To meet its overall aim, NeuRoPROBE will (1) develop chemical probes (CP) and PROTACs for TLX and Nurr1, (2) employ generative artificial intelligence (AI) for molecular design to accelerate CP and PROTAC development, (3) establish phenotypic cellular models in 3D settings to mimic neurodegeneration, and (4) use CPs and PROTACs in the phenotypic models for pharmacological control of TLX and Nurr1 to validate their modulation in neurodegeneration.
This challenging and highly multidisciplinary endeavor will profit from my strong interdisciplinary background in the field of NR ligand discovery and pharmacology as well as in AI-based molecular design. NeuRoPROBE will open new avenues towards regenerative treatments in neurodegeneration, close the gaps in pharmacological control of TLX and Nurr1, and substantially contribute to consolidating AI techniques for structural optimization.